Director, Patient Services
ITF Therapeutics
Director, Patient Services
ITF Therapeutics
Develops and commercializes rare-disease therapies
About This Role:
The Director, Patient Services, Neuromuscular Disorders (NMD) plays a critical role in facilitating patient access by leveraging their deep expertise in coverage, payer policies, and patient support ecosystems. This position owns the relationship and ultimate operational accountability for ITF’s patient support services and SP fulfillment.
The Director will lead the strategic design, business rules optimization, and daily operational execution of the ITF ARC (Access, Resources, and Care) program, ensuring an uninterrupted, high-touch journey for patients, caregivers, and providers navigating treatment with DUVYZAT™ (givinostat). Additionally, the Director will manage a specialized in-home lab monitoring program.
What You'll Do:
Exclusive Hub & SP Management
Business Rules & Operations
In-Home Lab Monitoring Program
Data Integration & Reporting
Cross-Functional Collaboration
Patient Access Support Programs
Required Skills:
Additional Information:
The base compensation range for this role is: $230,000 - $250,000. Base salary offered is determined through an analytical approach utilizing a combination of factors including, but not limited to, relevant skills & experience, job location, and internal equity.
Develops and commercializes rare-disease therapies
ITF Therapeutics is a division of Italfarmaco S.p.A. focused on developing and commercializing treatments for rare diseases in the U.S., especially Duchenne Muscular Dystrophy (DMD). The company works on early-stage research and clinical development, partnering with patient advocacy groups and clinical leaders to align programs with patient needs. Its lead program is DUVYZAT (givinostat), a histone deacetylase (HDAC) inhibitor aimed at DMD. Revenue comes from bringing these specialized therapies to market. Compared with competitors, ITF Therapeutics emphasizes collaboration with patient groups and clinicians, a pipeline-focused early-development approach, and a specialty in HDAC inhibitors for rare diseases. The company’s goal is to deliver effective treatments for rare-disease patients by advancing promising therapies through development and into commercialization.
Explore more opportunities at ITF Therapeutics